-$0.55 EPS Expected for Invitae Corporation (NVTA) This Quarter

Wall Street analysts expect Invitae Corporation (NYSE:NVTA) to post ($0.55) earnings per share (EPS) for the current quarter, according to Zacks Investment Research. Three analysts have issued estimates for Invitae Corporation’s earnings, with estimates ranging from ($0.70) to ($0.47). Invitae Corporation reported earnings per share of ($0.69) in the same quarter last year, which indicates a positive year over year growth rate of 20.3%. The company is scheduled to report its next earnings results on Monday, February 12th.

According to Zacks, analysts expect that Invitae Corporation will report full year earnings of ($2.45) per share for the current year, with EPS estimates ranging from ($2.58) to ($2.30). For the next financial year, analysts forecast that the company will post earnings of ($1.70) per share, with EPS estimates ranging from ($1.99) to ($1.38). Zacks’ earnings per share calculations are an average based on a survey of analysts that follow Invitae Corporation.

NVTA has been the topic of several analyst reports. BidaskClub raised Invitae Corporation from a “hold” rating to a “buy” rating in a report on Thursday, October 12th. Zacks Investment Research raised Invitae Corporation from a “sell” rating to a “hold” rating in a report on Friday, August 11th. Leerink Swann dropped their target price on Invitae Corporation from $14.00 to $12.00 and set an “outperform” rating on the stock in a report on Tuesday, November 7th. Finally, J P Morgan Chase & Co reaffirmed an “overweight” rating and set a $15.00 target price (up from $14.00) on shares of Invitae Corporation in a report on Wednesday, August 9th. Two research analysts have rated the stock with a sell rating, one has given a hold rating and three have issued a buy rating to the company. Invitae Corporation has an average rating of “Hold” and a consensus target price of $13.50.

ILLEGAL ACTIVITY WARNING: “-$0.55 EPS Expected for Invitae Corporation (NVTA) This Quarter” was reported by Sports Perspectives and is the sole property of of Sports Perspectives. If you are viewing this piece of content on another website, it was illegally stolen and reposted in violation of U.S. and international copyright & trademark law. The correct version of this piece of content can be accessed at https://sportsperspectives.com/2017/11/21/0-55-eps-expected-for-invitae-corporation-nvta-this-quarter.html.

A number of hedge funds have recently modified their holdings of NVTA. Perceptive Advisors LLC boosted its position in Invitae Corporation by 190.1% during the third quarter. Perceptive Advisors LLC now owns 1,884,500 shares of the medical research company’s stock worth $17,657,000 after purchasing an additional 1,235,000 shares in the last quarter. Orbimed Advisors LLC boosted its position in Invitae Corporation by 232.5% during the third quarter. Orbimed Advisors LLC now owns 1,518,197 shares of the medical research company’s stock worth $14,226,000 after purchasing an additional 1,061,531 shares in the last quarter. Ark Investment Management LLC boosted its position in Invitae Corporation by 30.4% during the second quarter. Ark Investment Management LLC now owns 982,170 shares of the medical research company’s stock worth $9,390,000 after purchasing an additional 229,189 shares in the last quarter. State Street Corp boosted its position in Invitae Corporation by 43.1% during the second quarter. State Street Corp now owns 577,978 shares of the medical research company’s stock worth $5,528,000 after purchasing an additional 174,016 shares in the last quarter. Finally, Northern Trust Corp boosted its position in Invitae Corporation by 39.0% during the second quarter. Northern Trust Corp now owns 433,113 shares of the medical research company’s stock worth $4,140,000 after purchasing an additional 121,409 shares in the last quarter. Institutional investors own 59.22% of the company’s stock.

Shares of Invitae Corporation (NYSE:NVTA) opened at $8.39 on Tuesday. Invitae Corporation has a 1-year low of $2.35 and a 1-year high of $8.46. The company has a quick ratio of 2.61, a current ratio of 2.61 and a debt-to-equity ratio of 0.33.

Invitae Corporation Company Profile

Invitae Corporation utilizes an integrated portfolio of laboratory processes, software tools and informatics capabilities to process deoxyribonucleic acid (DNA)-containing samples, analyze information about patient-specific genetic variation and generate test reports for clinicians and their patients.

Get a free copy of the Zacks research report on Invitae Corporation (NVTA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Invitae Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Invitae Corporation and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply